Kassum brings nearly 20 years of experience in the biopharmaceutical industry to Celsius.
He succeeds interim CEO Alexis Borisy, who will remain chairman of the company's board of directors.
Kassum joins the company from Obsidian Therapeutics, where he was a co-founder and served as chief operating officer and head of corporate development.
During this time, Kassum helped build Obsidian into a platform technology company and played a central role in the company's strategic partnership with Celgene.
Prior to Obsidian, Kassum spent seven years with Millennium Pharmaceuticals and Takeda, most recently as vice president, business development and strategy for Takeda Oncology, responsible for transactions, collaborations, alliance management and strategic planning.
He also led Takeda's global corporate development efforts, where he managed multiple acquisitions and divestitures.
Prior to Takeda, Kassum was an analyst covering healthcare equities for institutional investment firms, where he led diligence and investment decisions on numerous companies and pharmaceutical compounds.
He began his career as an investment banker with CIBC World Markets serving clients in the biotechnology and specialty pharmaceuticals industries. He holds an M.D. from University of Toronto and an A.B. from Cornell University.
Celsius Therapeutics is charting a new course of target and drug discovery by applying a systematic approach to single-cell sequencing of patient tissue, combining massive datasets, complex algorithms, and machine learning to discover first-in-class precision therapies with a transformative impact on the lives of patients with autoimmune diseases and cancer.
Celsius was launched in 2018, is backed by Third Rock Ventures and GV (formerly Google Ventures), and is based in Cambridge, Mass.
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories